UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Celgene Corporation
In a report published Friday, Jefferies reiterated its Buy rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $104.00 to $114.00.
Jefferies noted, “On its 4Q earnings call, CELG focused details around achieving the 2017 guidance laid out earlier this month. We are raising our price target from $104 to $114 as we are adding modest apremilast to our valuation and raising our expectations for Abraxane penetration in pancreatic cancer following positive Phase 3 data released yesterday.”
Celgene Corporation closed on Thursday at $97.49.
Latest Ratings for CELG
|Feb 2016||Leerink Swann||Initiates Coverage on||Market Perform|
|Jan 2016||Credit Suisse||Maintains||Outperform|
|Jan 2016||Credit Suisse||Initiates Coverage on||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.